Literature DB >> 2907704

Studies on the optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for preparation of a safe and potent pertussis vaccine.

R K Gupta1, S N Saxena, S B Sharma, S Ahuja.   

Abstract

The optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for the production of a safe and potent whole cell pertussis vaccine were investigated. Two bacterial harvests from B. pertussis strain 10536 were treated with glutaraldehyde, each with 0.025, 0.05 and 0.1% concentrations of glutaraldehyde for 10, 60 and 120 min. The nine types of glutaraldehyde-inactivated pertussis vaccine (GIPV) and conventional heat-inactivated pertussis vaccine (HIPV) preparations made from two bacterial harvests were comparatively evaluated for the mouse weight gain test (MWGT), potency, and the histamine-sensitization (HS) and leucocytosis-promoting-factor (LPF) tests. The minimum period for killing the B. pertussis organisms with glutaraldehyde was greater than 10 min for 0.025%, 10 min for 0.05% and 5 min for 0.1% concentration. The average loss in opacity varied from 5 to 10% for GIPV preparations and was 14% for HIPV preparations. The GIPV preparations except those inactivated with 0.025% glutaraldehyde for 10 min (GIPV-A) were much less toxic than the HIPV preparations in the MWGT. The GIPV-A preparations did not pass the MWGT. The GIPV preparations were also much less toxic in HS and LPF tests than the HIPV preparation. The potency of GIPV preparations inactivated with 0.05% glutaraldehyde for 10 min (GIPV-D) was similar to that of HIPV preparations. The prolonged treatments with glutaraldehyde reduced the potency. The GIPV-D preparation with good potency and less toxicity was found to be inactivated with glutaraldehyde under optimal conditions. All the preparations were innocuous in the abnormal toxicity test.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2907704     DOI: 10.1016/0264-410x(88)90099-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin.

Authors:  Y Lobet; C Feron; G Dequesne; E Simoen; P Hauser; C Locht
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

2.  A Proteomic Characterization of Bordetella pertussis Clinical Isolates Associated with a California State Pertussis Outbreak.

Authors:  Yulanda M Williamson; Hercules Moura; Jennifer Whitmon; Adrian R Woolfitt; David M Schieltz; Jon C Rees; Stephanie Guo; Heather Kirkham; Daniel Bouck; Edwin W Ades; Maria Lucia Tondella; George M Carlone; Jacquelyn S Sampson; John R Barr
Journal:  Int J Proteomics       Date:  2015-05-24

3.  Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis.

Authors:  Naser Mohammadpour Dounighi; Mehdi Razzaghi-Abyane; Mojtaba Nofeli; Hossein Zolfagharian; Fereshteh Shahcheraghi
Journal:  Jundishapur J Microbiol       Date:  2016-07-09       Impact factor: 0.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.